Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Wheeler

Showing results (401-410 of 455) with videos related to

Pageof 46
Sort By:
The New England Journal of Medicine|November 5, 2021
Daprodustat for the Treatment of Anemia in Patients Undergoing DialysisAjay K Singh, Kevin Carroll, Vlado Perkovic, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 23, 2021
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary AnalysisMeg Jardine, Zien Zhou, Hiddo J Lambers Heerspink, et al.
JAMA Network Open|December 11, 2024
The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial ProtocolSradha S Kotwal, Vlado Perkovic, Meg J Jardine, et al.
The New England Journal of Medicine|November 5, 2021
Daprodustat for the Treatment of Anemia in Patients Not Undergoing DialysisAjay K Singh, Kevin Carroll, John J V McMurray, et al.
Journal of the American Society of Nephrology : JASN|May 2, 2020
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized TrialMeg J Jardine, Zien Zhou, Kenneth W Mahaffey, et al.
Nature Medicine|July 3, 2024
Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trialGlenn M Chertow, Anna Marie Chang, G Michael Felker, et al.
Nature Medicine|May 25, 2024
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trialGlenn M Chertow, Anna Marie Chang, G Michael Felker, et al.
Transplantation Direct|August 9, 2016
Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney TransplantationAllison Tong, Klemens Budde, John Gill, et al.
Kidney International Reports|January 1, 2020
2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference ReportAngela Yee-Moon Wang, Tadao Akizawa, Sunita Bavanandan, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 5, 2021
The ASCEND-ND trial: study design and participant characteristicsVlado Perkovic, Allison Blackorby, Borut Cizman, et al.
Pageof 46

Showing results (401-410 of 455) with videos related to

Sort By:
Pageof 46
The New England Journal of Medicine|November 5, 2021
Daprodustat for the Treatment of Anemia in Patients Undergoing DialysisAjay K Singh, Kevin Carroll, Vlado Perkovic, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 23, 2021
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary AnalysisMeg Jardine, Zien Zhou, Hiddo J Lambers Heerspink, et al.
JAMA Network Open|December 11, 2024
The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial ProtocolSradha S Kotwal, Vlado Perkovic, Meg J Jardine, et al.
The New England Journal of Medicine|November 5, 2021
Daprodustat for the Treatment of Anemia in Patients Not Undergoing DialysisAjay K Singh, Kevin Carroll, John J V McMurray, et al.
Journal of the American Society of Nephrology : JASN|May 2, 2020
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized TrialMeg J Jardine, Zien Zhou, Kenneth W Mahaffey, et al.
Nature Medicine|July 3, 2024
Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trialGlenn M Chertow, Anna Marie Chang, G Michael Felker, et al.
Nature Medicine|May 25, 2024
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trialGlenn M Chertow, Anna Marie Chang, G Michael Felker, et al.
Transplantation Direct|August 9, 2016
Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney TransplantationAllison Tong, Klemens Budde, John Gill, et al.
Kidney International Reports|January 1, 2020
2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference ReportAngela Yee-Moon Wang, Tadao Akizawa, Sunita Bavanandan, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 5, 2021
The ASCEND-ND trial: study design and participant characteristicsVlado Perkovic, Allison Blackorby, Borut Cizman, et al.
Pageof 46